Results 241 to 250 of about 146,874 (392)

Managing hydrocephalus in patients with leptomeningeal disease: A multicenter retrospective analysis

International Journal of Cancer, Volume 157, Issue 8, Page 1613-1624, 15 October 2025.
What's New? Leptomeningeal disease is a highly palliative condition of tumor cell seeding that can cause symptomatic hydrocephalus. This multi‐center retrospective study of patients with leptomeningeal disease‐associated hydrocephalus compared the placement of ventriculoperitoneal shunts and Rickham reservoirs for cerebrospinal fluid drainage.
Obada T. Alhalabi, Lukas Klein, David Wasilewski, Amine Mellal, Carmen Büsken, Clara Buszello, Giulia Cossu, Ilker Y. Eyüpoglu, Andreas W. Unterberg, Peter Vajkoczy, Gabriele Schackert, Mahmoud Messerer, Martin Misch, Tobias Kessler, Wolfgang Wick, Christine Jungk, Ahmed El Damaty, Sandro M. Krieg, Tareq A. Juratli, Alexander Younsi   +19 more
wiley   +1 more source

Reversibility of Trastuzumab-Related Cardiotoxicity: New Insights Based on Clinical Course and Response to Medical Treatment [PDF]

, 2005
Michael S. Ewer, Mary T. Vooletich, Jean‐Bernard Durand, Myrshia Woods, Joseph R. Davis, Vicente Valero, Daniel J. Lenihan   +6 more
openalex   +1 more source

Directed-Complement Activation as a Novel Immunotherapeutic Approach for HER2-Breast Cancer. [PDF]

Immunotargets Ther
Seguin-Devaux C, Brandus B, Plesseria JM, Iserentant G, Servais JY, Pitiot A, Kanli G, Behrmann I, Schober R, Zimmer J, Cohen JHM, Dervillez X.   +11 more
europepmc   +1 more source

Tracking cancer‐related fatigue during chemotherapy: Insights from a comparative cohort study of early breast cancer patients

International Journal of Cancer, Volume 157, Issue 8, Page 1625-1636, 15 October 2025.
What's New? Cancer‐related fatigue is a multifactorial symptom commonly experienced by breast cancer patients treated with chemotherapy. Here, the authors investigated the temporal associations between cancer‐related fatigue and exercise capacity to better tailor exercise interventions during chemotherapy.
Joris Mallard, Elyse Hucteau, Roland Schott, Xavier Pivot, Allan F. Pagano, Thomas J. Hureau   +5 more
wiley   +1 more source

Primary care trust reverses decision not to fund trastuzumab [PDF]

, 2005
Susan Mayor
openalex   +1 more source

Functionalization of lipid nanoemulsions with humanized antibodies using plug-and-play cholesterol anchor for targeting cancer cells. [PDF]

Nanoscale Adv
Boide-Trujillo VJ, Mittelheisser V, Liu F, Lefebvre O, Andreiuk B, Anton N, Goetz JG, Klymchenko AS.   +7 more
europepmc   +1 more source

Pharmacokinetics of Trastuzumab in Haemodialysis

The Breast Journal, 2015
Gori, Stefania, Foglietta, Jennifer, Lunardi, Gianluigi, Inno, Alessandro, Cardinali, Barbara, MILLO, ENRICO, Del Mastro, Lucia, Nunzi, Emidio Giovanni, Crinò, Lucio   +8 more
openaire   +2 more sources

Conversion therapy with sintilimab combined with chemotherapy and apatinib in stage IV gastric cancer

International Journal of Cancer, Volume 157, Issue 8, Page 1637-1647, 15 October 2025.
What's New? In selected patients with stage IV gastric cancer, radical surgery after conversion therapy may increase survival benefit; however, there is currently no standard protocol for conversion therapy. This prospective, single‐arm, single‐center, phase 2 study evaluated the feasibility of adding immunotherapy to a conversion treatment regimen to ...
Yong Liu, Qiang Xue, Baogui Wang, Xuewei Ding, Rupeng Zhang, Xiaona Wang, Bin Ke, Xuejun Wang, Ning Liu, Jingyu Deng, Hongjie Zhan, Bin Li, Liangliang Wu, Mingzhi Cai, Li Zhang, Wenbai Huang, Peng Jin, Han Liang   +17 more
wiley   +1 more source

Eribulin plus Pyrotinib in Trastuzumab-Resistant, HER2-Positive Advanced Breast Cancer: A Single-Arm, Multicenter Phase II Trial (EPIC Trial). [PDF]

Drug Des Devel Ther
Li R, Wang M, Kong X, Ma J, Qi X, Song Z.   +5 more
europepmc   +1 more source

Recent Applications of Mesoporous Silica Nanoparticles in Gene Therapy

Advanced Healthcare Materials, Volume 14, Issue 26, October 7, 2025.
The review summarizes the synthesis of mesoporous silica nanoparticles (MSNs) with modifiable surface properties, functionalization strategies, mechanism of therapeutic payload release, and current applications in gene therapy, focusing on their capabilities in the targeted delivery of therapeutic nucleic acids, CRISPR‐Cas systems, and other genetic ...
Tamanna Binte Huq, Punnya Anil Kumar Jeeja, Sudip Kumar Dam, Sabya Sachi Das, Juan L. Vivero‐Escoto   +4 more
wiley   +1 more source